FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma By Ogkologos - September 30, 2026 13 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IGNYTE study Source RELATED ARTICLESMORE FROM AUTHOR Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant MOST POPULAR EMA Recommends to Extend Therapeutic Indications for Crizotinib in Paediatric Patients July 26, 2024 “My First Thought Was My Children:” Young Mom Diagnosed With Triple-Negative... July 20, 2020 Can Artificial Intelligence–Driven Chatbots Correctly Answer Questions about Cancer? October 3, 2023 Off Target: Investigating the Abscopal Effect as a Treatment for Cancer January 28, 2020 Load more HOT NEWS Fostering Black leadership in cancer research A Third Dose of BNT162b2 is Safe and Improves Humoural Immunity... Daratumumab Plus Bortezomib and Dexamethasone Regimen Significantly Prolongs OS in Patients... Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced...
